key: cord-0761577-pyjkg61q authors: Oto, Ozgur Akin; Ozturk, Savas; Arici, Mustafa; Veliooğlu, Arzu; Dursun, Belda; Guller, Nurana; Şahin, İdris; Eser, Zeynep Ebru; Paydaş, Saime; Trabulus, Sinan; Koyuncu, Sümeyra; Uyar, Murathan; Ural, Zeynep; Sadioğlu, Rezzan Eren; Dheir, Hamad; Koç, Neriman Sıla; Özer, Hakan; Durak, Beyza Algül; Gül, Cuma Bülent; Kasapoğlu, Umut; Oğuz, Ebru Gök; Tanrısev, Mehmet; Kuzgun, Gülşah Şaşak; Mirioglu, Safak; Dervişoğlu, Erkan; Erken, Ertuğrul; Görgülü, Numan; Özkurt, Sultan; Aydın, Zeki; Kurultak, İlhan; Öğütmen, Melike Betül; Bakırdöğen, Serkan; Kaya, Burcu; Karadağ, Serhat; Ulu, Memnune Sena; Güngör, Özkan; Bakır, Elif Arı; Odabaş, Ali Rıza; Seyahi, Nurhan; Yıldız, Alaattin; Ateş, Kenan title: Middle-term outcomes in renal transplant recipients with COVID-19: national, multicenter, controlled study date: 2022-02-14 journal: Clin Kidney J DOI: 10.1093/ckj/sfac045 sha: 5923420ab8c08f9222d2166d84140019b6b8c2ba doc_id: 761577 cord_uid: pyjkg61q BACKGROUND: In this study, we evaluated 3-month clinical outcomes of kidney transplant recipients (KTR) recovering from COVID-19 and compared them with a control group. METHOD: The primary endpoint was death in the third month. Secondary endpoints were ongoing respiratory symptoms, need for home oxygen therapy, rehospitalization for any reason, lower respiratory tract infection, urinary tract infection, biopsy-proven acute rejection, venous/arterial thromboembolic event, cytomegalovirus (CMV) infection/disease and BK viruria/viremia at 3 months. RESULTS: A total of 944 KTR from 29 different centers were included in this study (523 patients in the COVID-19 group; 421 patients in the control group). The mean age was 46 ± 12 years (IQR, 37–55), and 532 (56.4%) of them were male. Total number of death was 8 [7 (1.3%) in COVID-19 group, 1 (0.2%) in control group; p = 0.082]. The proportion of patients with ongoing respiratory symptoms [43 (8.2%) vs. 4 (1.0%); p < 0.001)] was statistically significantly higher in the COVID-19 group compared to the control group. There was no significant difference between the two groups in terms of other secondary endpoints. CONCLUSION: The prevalence of ongoing respiratory symptoms increased in the first three months post-COVID in KTRs who have recovered from COVID-19, but mortality was not significantly different. 19 patients have moderate to severe clinical manifestations and 5% progress to critical illness [1] . Solid-organ transplant (SOT) recipients have an increased vulnerability due to chronic immunosuppression, concomitant comorbidities, and the overall clinical course is worse than the general population [2] [3] [4] . Similarly, mortality rates in kidney transplant recipients (KTR) were reported to be higher than in non-transplant patient groups [5, 6] . KTR may have different complications from non-transplant patient groups in the post-disease period. In KTRs that survive COVID-19, graft functions may be adversely affected by ischemic, inflammatory, and nephrotoxic damage during the disease process. In addition, KTRs with COVID-19 are at higher immunological risk in the course of the disease due to drug and dose changes in immunosuppressive regimens, transfusion of blood products, and virus-related immunomodulation [7] . Evidence for middle-term outcomes in KTRs recovering from COVID-19 is very limited. Therefore, in this nationwide multicenter retrospective observational study, we included a cohort of KTRs after recovery from COVID-19 with at least 3 months of follow-up and with an aim to identify the clinical outcomes and to compare them with the control group. patients, and patients who lack outcome data were excluded. We recorded demographic data, reported comorbidities, non-immunosuppressive medications, The primary endpoint in the study was death in the third month. The secondary endpoints were ongoing respiratory symptoms, need of home oxygen therapy, rehospitalization for any reason, lower respiratory tract infection, urinary system infection, biopsy-proven acute rejection, venous/arterial thromboembolic event, CMV infection/disease BK viruria/viremia. Persistent cough and/or shortness of breath were defined as ongoing respiratory symptoms. For the control group, primary and secondary endpoints were also questioned during the same period (3 months). There were a total of 1006 patients in the raw data; 11 patients in the active COVID-19 period, 7 re-entered patients, 31 patients with negative RT-PCR and 13 patients without 3 rdmonth outcome data were excluded. A total of 944 (523 COVID-19 patients, 421 controls) KTRs from 29 different centers were included in the study. (Figure 1 Table 4 ). Clinical and laboratory characteristics of groups according to primary and secondary outcomes Table 5 ). Those who died had older age, severe COVID-19 clinic at the time of admission, needed hospitalization, required ICU, required RRT during the hospital follow-up period, required rehospitalization, ongoing respiratory symptoms, lower respiratory infection, and needed home oxygen therapy (Table 3 ). There was no statistically significant difference between the dead and the survivors in terms of donor type, transplantation duration, smoking habit, gender, CMV infection/disease, acute rejection, BK infection, venous/arterial thromboembolic event, and urinary system infection. In this multicenter, retrospective, controlled follow-up study of renal transplant recipients recovering from COVID-19, although it did not reach statistical significance, the number of patients who died in the post-COVID era was higher than the control group. We found persistence of respiratory symptoms without increased risk of acute rejection, BK and CMV infection, thromboembolic event or urinary tract infection. As far as we know, this is the first controlled follow-up study in renal transplant recipients who have recovered from COVID-19. There are growing concerns about possible long-term sequelae of COVID-19 [11] . The inflammatory damage and severe tissue sequelae characteristic of particularly severe forms of the disease may affect multiple organ systems. Some patients who recovered from COVID-19 develop persistent or new symptoms lasting weeks or months. This condition is defined as "long COVID", "Long Haulers" or "Post COVID syndrome" [12] . Several publications showed that COVID-19 causes significant pulmonary sequelae. Although it was not a controlled study and was not conducted specifically for the transplant population, in a follow-up study evaluating recovered from COVID-19 478 patients, the incidence of new-onset dyspnea was 16%. Also, four months after hospitalization for COVID-19, a proportion of patients developed previously unreported symptoms and lung scan abnormalities were common in this group [13] . Similarly, in another study, dyspnea, chest pain and cough were found in 37%, 16% and 14% of patients between 3 weeks and 3 months, after discharge of hospital admission by COVID-19, respectively [14] . In our patient group, the rate of patients with persistent respiratory symptoms was lower than in the literature. This may be related to the fact that many of our patients had mild COVID-19 or our patients were relatively young. The mean age was 60.9±16.1 in the study of Morin et al., and between 49±15 and 63.2±15.7 in the review of Cares-Marambio et al [13, 14] . However, the mean age in our study was 46.0±12.0 years. In addition, we found that death was more common in the patient group whose respiratory symptoms continued. However, we do not have enough evidence to state that the deaths are related to COVID-19. This result may be an important finding emphasizing that the patient group with persistent respiratory symptoms should be followed closely after discharge. It is unclear whether changes in immunosuppressive therapy during active COVID-19 or possible persistent inflammation during the recovery period are associated with a higher risk of transplant complications such as rejection or infection. There are several reports that SARS-CoV-2 infection could cause exhaustion of T cells and particularly CD8+ T cells, thus leading to viral replication [15, 16] . We did not detect an increase in the risk of CMV and BKV in our patient group after recovery from COVID-19. This may be related to the short follow-up period. It is unclear whether there will be an increase in the frequency of viral infections in the long term. Numerous studies have shown evidence of COVID-19-related coagulopathy and an increased risk of arterial and venous thromboembolic events [17] [18] [19] [20] . We did not detect a significant The results of our study should be evaluated according to its strengths and potential limitations. Among the strengths, to the best of our knowledge, this is the first multicenter, considering the chaotic environments during the pandemic period, these data can be considered close to real practical life data despite all its limitations. In conclusion, the prevalence of persistent respiratory symptoms after COVID-19 in KTRs was higher than in KTRs without COVID-19, but mortality was not significantly different. None declared. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Covid-19 in kidney transplant recipients: a systematic review of the case series available three months into the pandemic SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort study Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study Is COVID-19 infection more severe in kidney transplant recipients? Predicting the outcome of COVID-19 infection in kidney transplant recipients Common viral infections in kidney transplant recipients Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration Guidance to COVID-19 (SARS Cov2 Infection) (Scientific Board Study) Republic of Turkey Ministry of Health Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review Long COVID: An overview Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19 Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis Resurgence of BK virus following Covid-19 in kidney transplant recipients Immunology of COVID-19: Current State of the Science Animal communication: when i'm calling you, will you answer too? Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia COVID19 coagulopathy in Caucasian patients Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients Nonsurvivors N: 8 P value Study groups Tx Duration, years, median Donor Type Fisher's exact test or Mann-Whitney U test Abbreviations: IQR interquartile range, CMV cytomegalovirus, ICU intensive care unit